TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05806307

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: (15 patient): who will receive 800 microgram (tablet 200mcg X 4) misoprostol (Misotac 200 mcg, SIGMA pharmaceutical, Egypt) rectally one and half hour before operation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tourniquet
Description: (15 patient): The operation will be performed with the use of Foleys catheter as an improvised tourniquet applied at the base of the uterus then infiltration myometrium overlying the leiomyoma with a solution composed of Bupivacaine Hcl 0.25% and 0.5 mg of epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: (15 patients): intramural; preparation of 100 μg of carbetocin ((Pabal, Ampoule 100 mcg in 1 ml, Carbetocin; FERRING, North York, Canada) diluted within 10 cm of saline (0.9%) in sterile syringe then will inject the substance into the multiple sites intramyometrial in a circumferential manner 1-2 cm away from the margins of the myoma in the planned uterine-incision site just before uterine incision for myoma extraction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: (15 patients): who will receive oxytocin 40 I.U. intramyometrially (Syntocinon, Ampule 10 I.U. in 1 ml, Oxytocin; NOVARTIS, Basel, Switzerland) then will inject the substance into the multiple sites intramyometrial in a circumferential manner 1-2 cm away from the margins of the myoma in the planned uterine-incision site just before uterine incision for myoma extraction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combined TXA and ethamsylate
Description: (Patient 15): will receive 1 g tranexamic acid (2 ampoules of kapron 500 mg, kapron®, Amoun, Egypt) and 500 mg ethamsylate (2 ampoule of ethamsylate 250 mg, Dicynone, OM pharma, Geneva, Switzerland) IV 10 minutes before skin incision by slowly intravenous injection Then infusion was applied continuously for 24 hours within 1 liter of saline as 1 mg/kg/hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Description: 15 patient intramyometrial injection of one ampoule of vasopressin containing 20 units in1 ml after dilution in 19 ml of normal saline during myomectomy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride 0.5 % Injectable Solution epinephrine
Description: 15 patient infiltration of the serosa and / or myometrium overlying the leiomyoma before uterine incision with a solution composed of 50 ml Bupivacaine Hcl 0.25% (Bucain® Weimer pharma, for Actavis Group PTC) and 0.5 mg of epinephrine Hcl (2 vials of Epinephrine® 0.25mg/1ml Misr Co. for Pharmaceutical Industries).
Study: NCT06600880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amyvid
Description: Amyloid PET tracer Amyvid (18F- Florbetapir) will be stored in their original container with proper radiation shielding at 25 °C and only handled by properly trained personnel in the handling and administration of radioactive materials, which requires employing proper radiation protection procedures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6240
Description: \[18F\]MK-6240 will be synthesized, purified, and formulated at the local radiochemistry synthesis laboratory and will be administered as a sterile, pyrogen-free solution by IV injection. The radiotracer \[18F\]MK-6240 is supplied in a sterile, ready-to-use solution, direct from the Columbia University PET Center. It is supplied for a targeted calibration time, the precise volume to be administered at a given time can be calculated based on the decay of F-18. Only personnel properly trained in the handling and administration of radioactive materials should handle \[18F\]MK-6240. Usual radiation protection procedures should be used for handling radiotracers, including shielding (lead or tungsten containers/shields), and personal protective equipment including gloves. There are no specific procedures required for the handling of \[18F\]MK-6240. The expiry of \[18F\]MK-6240 is eight hours from the time at End of Synthesis (EOS).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dotarem
Description: FDA-approved medication. Dotarem will be handled in accordance with the CUMC Research Pharmacy procedures and NYP policy P168, Version 4. Dotarem will be used according to its labeling. 0.2 ml/kg.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Blood samples will be collected through an intravenous catheter or a finger prick during screening, on the day of the FUS treatment and the follow up examinations (week 3 and month 3). These samples will be processed to assess any blood content changes induced by the focused ultrasound treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UR5e
Description: Universal Robots robotic arm used for the accurate positioning of the neuronavigation-guided single-element focused ultrasound transducer with respect to the patient's head.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urine test
Description: Urine test required following the MRI and PET Centers policy used clinically for pregnancy screening
Study: NCT06588010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OM-89 [Uro-Vaxom® Capsule]
Description: 1st phase and 2nd phase : 1 capsule per day of OM-89 for 90 consecutive days followed by a period of 90 days without treatment, then one capsule per day of OM-89 for 10 consecutive days each month for three months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OM-89 [Uro-Vaxom® Capsule] OM-89 placebo [Uro-Vaxom® Capsule placebo]
Description: 1st phase: 1 capsule per day of placebo for 90 consecutive days followed by a period of 90 days without treatment, then one capsule per day of placebo for 10 consecutive days each month for three months.~Then 2nd phase: 1 capsule a day of OM-89, for 90 consecutive days followed by a period of 90 days without treatment, then one capsule a day of OM-89 6mg for 10 consecutive days each month for three months.
Study: NCT06597682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral prednisone tablet treatment
Description: Oral prednisone tablet treatment, taking 40mg (8 tablets) daily, with a reduction of 1 tablet (5mg) per week for the first 2 weeks, followed by a reduction of 0.5 tablets (2.5mg) per week from the 3rd week onwards, for a total duration of 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral prednisone tablet treatment
Description: Oral prednisone tablet treatment, taking 40mg (8 tablets) daily, with a reduction of 1 tablet (5mg) per week for the first 2 weeks, followed by a reduction of 0.5 tablets (2.5mg) per week from the 3rd week onwards, for a total duration of 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhalation treatment with budesonide/formoterol
Description: Inhalation treatment with budesonide/formoterol powder inhaler (160µg; 4.5µg), inhaled twice daily, for a total duration of 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination therapy with cognitive enhancer drugs and oral prednisone
Description: Combination therapy with cognitive enhancer drugs and oral prednisone , starting dose of prednisone is 1mg per kilogram of body weight, with a reduction of 1 tablet (5mg) every 2 weeks, for a total duration of 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo (cornstarch tablets)
Description: Oral placebo (cornstarch tablets), taking 8 tablets daily, with a reduction of 1 tablet (5mg) per week for the first 2 weeks, followed by a reduction of 0.5 tablets (2.5mg) per week from the 3rd week onwards, for a total duration of 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo (cornstarch tablets)
Description: Oral placebo (cornstarch tablets), taking 8 tablets daily, with a reduction of 1 tablet (5mg) per week for the first 2 weeks, followed by a reduction of 0.5 tablets (2.5mg) per week from the 3rd week onwards, for a total duration of 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhalation of placebo (saline solution)
Description: Inhalation of placebo (saline solution), inhaled twice daily, for a total duration of 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Combination therapy with cognitive enhancer drugs and oral placebo (cornstarch tablets)
Description: Combination therapy with cognitive enhancer drugs and oral placebo (cornstarch tablets), starting dose of cornstarch tablets is 1mg per kilogram of body weight, with a reduction of 1 tablet (5mg) every 2 weeks, for a total duration of 6 months.
Study: NCT06600932

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TMS
Description: TMS treatment in this study indicates a non-invasive procedure called transcranial magnetic simulation (TMS) on visual cortex. The treatment intensity is set as 80% of the threshold of each participant. The treatment will be conducted every day for consecutive 5 days.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: control group
Description: The control treatment is a sham-controlled procedure, in which participants will be exposed to the recorded sounds of TMS pulses but without real magnetic stimulation.
Study: NCT06604741

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigned Interventions for LVIMT
Description: IMT is a form of exercise designed to strengthen the muscle involved inhalation, primarily the diaphragm and intercostal muscles.~The LVIMT group will perform IMT once daily, 5 days a week, maintaining 60% of maximal inspiratory pressure (MIP) throughout the 6-week intervention.~The intervals are typically longer in duration (e.g., 2-4 minutes) with a work-to-rest ratio of 1:1 or 1:0.5.~POSITION: rested and seated position. FREQUENCY: more frequency, once a day. 2-3 sessions per week. INTENSITY: Low resistance. Only 60%% MIP. TIME: shorter duration of 10-20 mint.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigned interventions for HVIMT
Description: The HVIMT group is trained twice daily, with the morning session matching the LV-IMT protocol, and an additional afternoon session. The HVIMT group also experienced a progressive increase in intensity, starting at 60% MIP and reaching 80% by the end of the study. LVIMT works for beginner or individuals with limited respiratory capacity while HVIMT is used for individual with high baseline respiratory fitness.~The intervals are typically shorter in duration (e.g., 30 seconds to 2 minutes) with a work-to-rest ratio of 1:1 or 1:2.~POSITION; Seated upright position. FREQUENCY: more frequency two session per week. 4-5 sessions per week. INTENSITY: high resistance. 60%-80% MIP.~(gradual increment the load by 10% every 2 weeks to reach 80% MIP)~TIME: longer duration 20-30 mint.
Study: NCT06595056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-technology MVPA intervention
Description: Participants will receive a one-on-one counseling session and access to an individually tailored multi-media website. Key intervention components will be reinforced through text messaging to aid goal setting, a physical activity tracker (Fitbit) to set goals, track and log activity, and access to a study Instagram account to reinforce exposure to web content.
Study: NCT06603415

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total thyroidectomy
Description: Total thyroidectomy (with preservation of bilateral recurrent laryngeal nerves and all parathroid glands) for histopathology
Study: NCT06599411

Intervention type: OTHER
Intervention: Sampling
Description: Collection of an additional volume of blood Superficial skin biopsy Skin swab

Intervention type: OTHER
Intervention: Sampling
Description: Collection of an additional volume of blood Preservation of post-operative skin remnants Skin swab
Study: NCT06599528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-R (Test-Reference drug)
Description: T: SJ04 (Test drug) R: Ovidrel® (Referecne drug) 250 μg of SJ04 injection or Oviderl®, administered subcutaneously once at two week intervals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-T (Reference-Test drug)
Description: R: Ovidrel®(Referecne drug) T: SJ04 (Test drug) 250 μg of SJ04 or Oviderl®, administered subcutaneously once at two week intervals.
Study: NCT06299475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online counseling and invitation
Description: Online counseling - An educational video including contraceptive models, four key questions and an effectiveness chart (the LOWE intervention material).~Invitation to a clinic - access by weblinks to a regional or national website
Study: NCT06594601

Intervention type: PROCEDURE
Intervention: lung recruitment potential assessed by 3D EIT
Description: Patients were ventilated based on the ARDS-Net suggestions. The patients were kept at supine position. The lung recruitment potential assessed by 3D EIT was as follows:~1. All patients were under pressure control mode (driving pressure 12-15 cmH2O with a tidal volume of 6-8 ml/kg predicted body weight, respiration rate12-15 bpm).~2. PEEP was switched to a zero end-expiratory pressure (ZEEP) for 10 min, and FiO2 was titrated to obtain peripheral oxygen saturation (SpO2 ) \&gt; 90%.~3. PEEP was stepwise increase from 0 to 15 cmH2O PEEP in steps of 5cm H2O every 3min.And 3D EIT was used to assess lung recruitment potential.

Intervention type: PROCEDURE
Intervention: PEEP titration by 3D eit
Description: Patients were ventilated based on the ARDS-Net suggestions. The patients were kept at supine position. The PEEP titriatino by 3D EIT fwas as follows:~1. All patients were under pressure control mode (driving pressure 12-15 cmH2O with a tidal volume of 6-8 ml/kg predicted body weight, respiration rate12-15 bpm).~2. RM: PEEP was switched to a 21cmH2O for 2min, and FiO2 was titrated to obtain peripheral oxygen saturation (SpO2 ) ≥90%.~3. PEEP was stepwise decrease from 21 to 0 cmH2O PEEP in steps of 3cm H2O every 2min.~4. 3D EIT was used to monitor regional ventilation distribution during PEEP titration.
Study: NCT06603038

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gainful Daily Performance Greens
Description: Daily supplementation for 28 days
Study: NCT06603233

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: The Difference Between The AI Model and Dentists Group
Description: The clinical feasibility of the best performing model, statistical hypothesis tests are performed that compares the predictions of the AI model with the assessments from three dentists.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Deep Learning Models
Description: DeepLabV3+, Mask R-CNN (Detectron2), YOLOv8, U-Net, Super Vision U-net and U-Net Transformer were trained on 354 images and tested on 79 images.
Study: NCT06589232

Intervention type: OTHER
Intervention: Food allergy
Description: Threshold dose to pistachio
Study: NCT06588114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antistress Ball
Description: Hemodialysis patients will be asked to look away by giving an antistress ball to the non-arteriovenous fistula hand and squeezing and then loosening the ball during the arteriovenous fistula intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Valsalva maneuver
Description: The Valsalva maneuver is a breathing method that can slow down a heart with a very fast pulse rate. In this maneuver, the individual breathes strongly through his mouth while his nose is tightly closed, and while holding his breath, a strong tension occurs. This maneuver allows the heart to react and return to a normal rhythm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin cooling
Description: Hemodialysis patients will be provided with lowering of skin temperature with a skin cooling device by the researcher for 10 minutes before arteriovenous fistula intervention is made to hemodialysis patients
Study: NCT06593509

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Maquet,Servo I.
Description: Model number: 06487800, Serial Number: 19761, SKU#: Inv-00344191, Made in Sweden

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vapotherm
Description: INC ,100 domain drive Exeter, NH 03833, Made in U.S.A

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: venturi mask
Description: Intersurgical Ltd, Crane House, Molly Millars Lane, Wokingham, Berkshire, RG41 2RZ, UK.,REF. 1107085, LOT,31757961
Study: NCT05523089

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: Sterile normal saline for injection

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CD388
Description: CD388 liquid for injection

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CD388
Description: CD388 liquid for injection

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CD388
Description: CD388 liquid for injection

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CD388
Description: CD388 liquid for injection

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CD388
Description: CD388 liquid for injection
Study: NCT05744752

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lead Acetate
Description: The oral LD50 of lead acetate is 390mg/kg body weight. The experimental group B, C, and D will receive a single dose of 19.5 mg/kg b.w (1/120th of LD50),31 daily dissolved in distilled water and given by oral gavage method for 12 weeks. Lead acetate Pb(CH3COO)2x3H2O, will be purchased from Sigma-Aldrich Chemie (Germany).
Study: NCT05491811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: Participants will receive Ensartinib 225 mg oral once daily from baseline until disease progression, unacceptable toxicity, withdrawal of consent or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Participants will receive 7.5 mg/kg intravenous on Day 1 of 21 day cycles (every 3 weeks) from baseline until disease progression, unacceptable toxicity, withdrawal of consent or death.
Study: NCT04810091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat Ethyl
Description: Given PO
Study: NCT06601426

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CSP
Description: cold snare polypectomy
Study: NCT06601582

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of a operative blood salvage system
Description: The surgical team will use a operative blood salvage system
Study: NCT06604663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activation of the CDSS system
Description: Activation of the CDSS system, whereby outreach workers and clinicians have access to and ability to act upon lists of patients who are at highest risk of missing their upcoming clinical appointment.
Study: NCT06590012

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take the placebo capsules in addition to standard treatment for a year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tertinat
Description: Participants will take Tertinat capsules in addition to standard treatment for a year.
Study: NCT06595537

Intervention type: DEVICE
Intervention: Hand held ultrasound
Description: Determination of gastric feeding tube position with the use of Lumify handheld ultrasound
Study: NCT06690359

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: IM19 chimeric antigen receptor T cell injection
Description: IgA nephropathy:~The investigators plan to recruit IgA nephropathy subjects with urinary protein and renal dysfunction who meet the inclusion and exclusion criteria. They will receive Beijing Zaimiao Biological IM19 CAR-T cell infusion therapy at doses of 0.5 × 10 \^ 8 and 1 × 10 \^ 8 CAR-T cells, with 3 subjects enrolled at each dose~Primary membranous nephropathy:~The investigators plan to recruit primary membranous nephropathy subjects who meet the inclusion and exclusion criteria and receive IM19CAR-T cell infusion therapy at doses of 0.5 × 10 \^ 8 and 1 × 10 \^ 8 CAR-T cells, with 3 subjects enrolled at each dose

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: IM19 chimeric antigen receptor T cell injection
Description: IgA nephropathy:~The investigators plan to recruit IgA nephropathy subjects with urinary protein and renal dysfunction who meet the inclusion and exclusion criteria. They will receive Beijing Zaimiao Biological IM19 CAR-T cell infusion therapy at doses of 0.5 × 10 \^ 8 and 1 × 10 \^ 8 CAR-T cells, with 3 subjects enrolled at each dose~Primary membranous nephropathy:~The investigators plan to recruit primary membranous nephropathy subjects who meet the inclusion and exclusion criteria and receive IM19CAR-T cell infusion therapy at doses of 0.5 × 10 \^ 8 and 1 × 10 \^ 8 CAR-T cells, with 3 subjects enrolled at each dose
Study: NCT05642039

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Course
Description: Participants will attend a weekly 1.5-hour class over a 6-week period via Zoom. Participants will also be required to listen to guided practice audio recordings that are 12-20 minutes long and complete a weekly homework log detailing all audio recordings completed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HS Educational Course
Description: Participants will meet for 10 -15 minutes once a week over a 6-week period. The course will be administered verbally or with the use of PowerPoint slides.
Study: NCT05908461

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Childhood Friendship Project
Description: Classroom-based intervention where teachers will implement 8 10-minute puppet shows, 7 5-minute active gross motor activities to reinforce the social skill of the week, and 7 5-minute passive rehearsal activities such as making their own puppet and practicing the steps of the week. Up to three 1 hour in vivo behavioral reinforcement periods will occur per week and during these free play sessions teachers and the main puppet will use developmentally appropriate praise to reinforce the use of the social skills of the week.
Study: NCT05229887

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nostril-Tragus-Length
Description: Endotracheal tube depth is determined by measuring the newborn's nasal septum-tragus length (NTL) and adding 1cm.~The NTL is described as the distance from the base of the nasal septum to the tragus of the ear.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vocal cord marking
Description: The endotracheal tube has markings on the tube, which are called vocal cord markings, which will be used to provide a guidance to how deep to place the ETT into the trachea.